Menlo Park, CA – December 13th 2024 – Deepcell, a leader in AI-powered single-cell analysis, is thrilled to announce that its flagship technology, the REM-I platform, has been named the #1 innovation in The Scientist’s prestigious Top 10 Innovations contest. This annual competition highlights groundbreaking products launched between January 2023 and July 2024 that are poised to transform scientific research and clinical applications.
The REM-I platform, launched in April 2024 with commercial placements in Top Pharma, Academic and Government institutions combines advanced artificial intelligence with high-resolution brightfield imaging and microfluidics to revolutionize the way researchers explore cellular heterogeneity. Designed to deliver unbiased, real-time insights into cellular morphology and functionality, REM-I allows scientists to uncover subtle phenotypic differences and sort morphologically distinct cell populations that may be overlooked through manual methods.
“This recognition underscores the transformative potential of REM-I to redefine how researchers and clinicians approach single-cell analysis,” said Maddison Masaeli, Deepcell’s co-founder and CEO. “By integrating AI, high-throughput imaging, and precise sorting capabilities, REM-I offers unparalleled opportunities to unlock new biological insights and improve translational research outcomes.”
Deepcell’s REM-I platform is already making an impact in the field. Clinical bioinformatician and Deepcell scientific advisory board member Dr. Peter van der Spek from Erasmus Medical Center has used the REM-I platform in translational research projects, including investigations into kidney transplant rejection. Reflecting on his findings, Dr. van der Spek remarked, “We observed cell morphologies that have never been seen before by pathologists. This opens up entirely new dimensions of biology and enhances our ability to understand and treat complex conditions.”
The REM-I platform’s innovative capabilities and flexible pricing models have made it an accessible and indispensable tool for researchers worldwide.
Deepcell extends its gratitude to The Scientist and its panel of independent judges for this honor and reaffirms its commitment to advancing research through cutting-edge technology.
For more information about the award as well as other awardees please visit https://www.the-scientist.com/2024-top-10-innovations-72342. For more information about the REM-I platform and its applications, please visit www.deepcell.com.
About Deepcell
Deepcell is a life science company which brings artificial intelligence to cell biology, unlocking a new field of high-dimensional biological discovery known as morpholomics. Through Deepcell’s AI-powered imaging and microfluidics solution, the REM-I Platform, the company is enabling a new scale of cell biology research and single cell analysis leveraging cellular morphology for unbounded discovery. Deepcell’s platform leverages its artificial intelligence model, the Human Foundation Model, to identify and sort cells based on morphological distinctions helping power basic and translational research and offering future applications in diagnostic testing and therapeutics targeting. The company was spun out of Stanford University in 2017 and has raised nearly $100 million in venture capital. It is based in Menlo Park, California. Learn more at www.deepcell.com or follow us on LinkedIn, Twitter, and YouTube.
Media Contact
info@deepcellbio.com
